Name: REVELATION BIOSCIENCES INC (REVB) Stock
Brand: REVELATION BIOSCIENCES INC
Rating: 3.5 (3 reviews)

REVB Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Chartmill

REVELATION BIOSCIENCES INC (NASDAQ:REVB) Reports Q3 2025 Loss, Announces Groundbreaking Clinical Data and Improved Cash Runway

6 days ago - By: Benzinga - Mentions: PACS GNTA SCYX NCNA ...

12 Health Care Stocks Moving In Thursday's After-Market Session

6 days ago - By: ACCESS Newswire

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

16 days ago - By: Benzinga - Mentions: SGMO NNVC CYCN CNSP ...

12 Health Care Stocks Moving In Monday's After-Market Session

20 days ago - By: ACCESS Newswire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

a month ago - By: ACCESS Newswire

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

a month ago - By: ACCESS Newswire

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

3 months ago - By: ACCESS Newswire

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

3 months ago - By: ACCESS Newswire

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

3 months ago - By: ACCESS Newswire

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

3 months ago - By: Stocktwits

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

3 months ago - By: ACCESS Newswire

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

4 months ago - By: Revelation Biosciences, Inc.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

4 months ago - By: Revelation Biosciences, Inc.

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

4 months ago - By: Revelation Biosciences, Inc.

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

5 months ago - By: Stocktwits

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

5 months ago - By: Revelation Biosciences, Inc.

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

6 months ago - By: Yahoo Finance - Mentions: 1456 URBN KSS DECK ...

S&P lowers outlook on Volvo Cars rating citing US tariffs, competition in China

6 months ago - By: Yahoo Finance - Mentions: ESLT CTKB KROS VREX ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

6 months ago - By: Revelation Biosciences, Inc.

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

6 months ago - By: Revelation Biosciences, Inc.

REVELATION BIOSCIENCES INC (REVB) Stock News

REVB Latest News, Press Relases and Analysis

REVELATION BIOSCIENCES INC (NASDAQ:REVB) Reports Q3 2025 Loss, Announces Groundbreaking Clinical Data and Improved Cash Runway

12 Health Care Stocks Moving In Thursday's After-Market Session

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

12 Health Care Stocks Moving In Monday's After-Market Session

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

S&P lowers outlook on Volvo Cars rating citing US tariffs, competition in China

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering